Cell & Gene Therapy Market - Global Outlook and Forecast 2020-2025
In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global Cell and Gene Therapy Market Report
The global cell and gene therapy market by revenue is expected to grow at a CAGR of over 30.90% during the period 2019–2025.
The global cell and gene therapy market is one of the fastest-growing segments in the regenerative medicine market. The market is expected to grow at a faster pace during the forecast period. The demand can be attributed to the growing prevalence of several chronic diseases such as cancer, cartilage related problems, wounds, diabetic foot ulcer, genetic disorders, and other rare diseases across the globe. The prevalence of cancer and diabetes is increasing in the global population, which is influencing the growth of the market. There is a large unmet need in the treatment available, which is filled by cell and gene therapies. The market is growing due to the increased availability of funding from various public and private institutions. Besides, there is increased support from regulatory bodies for product approval. Several governments are creating awareness of cell and gene therapies in the population.
The following factors are likely to contribute to the growth of the cell and gene therapy market during the forecast period:
Cell And Gene Therapy Market Segmentation
The global cell and gene therapy market research report includes a detailed segmentation by product, disease, end-user, and geography. In 2019, the cell therapy segment accounted for a market share of over 53% in the global cell and gene therapy market. The segment is expected to grow at a steady rate during the forecast period due to the increase in the target population and the rise in the number of countries preferring cell therapies in their patients. Increased therapeutic benefits are attracting several countries to invest in this technology and conduct a high number of clinical trials. However, the lack of advanced infrastructure in developing countries is hindering the growth of the segment.
In 2019, the oncology segment accounted for a share of over 40% in the global cell and gene therapy market. Oncology has been one of the targets of intense research for the gene therapy procedures & approach. More than 60% of on-going gene therapy clinical trials are targeting cancer. The segment is expected to grow at a promising rate on account of the high prevalence of cancer diseases, especially in low and middle-come countries. The market is growing at a double-digit CAGR, which is expected to help the segment as many cell and gene therapy for cancer are commercially available.
The dermatology application segment in the cell and gene therapy includes wound care management among patients. Vendors are focusing on the development and commercialization of advanced wound care products for the treatment of chronic and acute wounds, thereby increasing the growth of the wound care market. The increased pervasiveness of diabetics is increasing acute and chronic wounds, including surgical wounds, pressure ulcers, diabetic foot ulcers, and other wounds.
In 2019, the oncology segment accounted for a share of over 40% in the global cell and gene therapy market. Oncology has been one of the targets of intense research for the gene therapy procedures & approach. More than 60% of on-going gene therapy clinical trials are targeting cancer. The segment is expected to grow at a promising rate on account of the high prevalence of cancer diseases, especially in low and middle-come countries. The market is growing at a double-digit CAGR, which is expected to help the segment as many cell and gene therapy for cancer are commercially available.
The dermatology application segment in the cell and gene therapy includes wound care management among patients. Vendors are focusing on the development and commercialization of advanced wound care products for the treatment of chronic and acute wounds, thereby increasing the growth of the wound care market. The increased pervasiveness of diabetics is increasing acute and chronic wounds, including surgical wounds, pressure ulcers, diabetic foot ulcers, and other wounds.
Segmentation by Product
In 2019, North America accounted for a share of over 60% of the global cell and gene therapy market. There are more than 530 regenerative medicine companies, including cell and gene therapy manufacturing developers. The number of products approved in North America grew significantly in 2019, with developers filed for marketing authorization for 10+ regenerative medicines, many of which we expect to be approved in 2020. Within the next 1–2 years, the number of approved gene therapies is expected to double. The US and Canada are the major contributors to the cell and gene therapy market in North America. Regulatory bodies are supporting several investigational products, fast track approvals, RMAT designation for the faster approval of the product into the market. The alliance for regenerative medicine and Medicare and Medicaid is working together to bring the structured reimbursement channels for cell and gene therapies.
Segmentation by Geography
The global cell and gene therapy market is highly dynamic and characterized by the presence of several global, regional, and local vendors offering a wide range of therapies. Dendreon, Gilead Sciences, Novartis, Organogenesis, Osiris Therapeutics, Vericel, Amgen, and Spark Therapeutics are the leading players in the market with significant shares. Vendors such as NuVasive, APAC Biotech, Nipro, Orthocell, bluebird bio, J-TEC, and Terumo are the other prominent players in the market with a presence, especially in the cell therapy market. Most leading players are focusing on implementing strategies such as product launches and approvals, marketing and promotional activities, acquisitions, increased R&D investments, and strengthening their distribution networks to enhance their share and presence in the market.
Prominent Vendors
1. What is the cell and gene therapy market size and growth rate during the forecast period?
2. What are the factors impacting the growth of the cell and gene therapy market share?
3. How is the growth of the healthcare segment affecting the growth of the cell and gene therapy market?
4. Who are the leading vendors in the cell and gene therapy market, and what are their market shares?
5. Which product type/ end-user type/region is generating the largest revenue in the Asia Pacific region?
The global cell and gene therapy market by revenue is expected to grow at a CAGR of over 30.90% during the period 2019–2025.
The global cell and gene therapy market is one of the fastest-growing segments in the regenerative medicine market. The market is expected to grow at a faster pace during the forecast period. The demand can be attributed to the growing prevalence of several chronic diseases such as cancer, cartilage related problems, wounds, diabetic foot ulcer, genetic disorders, and other rare diseases across the globe. The prevalence of cancer and diabetes is increasing in the global population, which is influencing the growth of the market. There is a large unmet need in the treatment available, which is filled by cell and gene therapies. The market is growing due to the increased availability of funding from various public and private institutions. Besides, there is increased support from regulatory bodies for product approval. Several governments are creating awareness of cell and gene therapies in the population.
The following factors are likely to contribute to the growth of the cell and gene therapy market during the forecast period:
- Increase in Strategic Acquisition Activities
- Increased Funding for Cell & Gene Therapy Products
- Expanding Applications of Cell and Gene Therapies
- Increased in the Patient Pool
Cell And Gene Therapy Market Segmentation
The global cell and gene therapy market research report includes a detailed segmentation by product, disease, end-user, and geography. In 2019, the cell therapy segment accounted for a market share of over 53% in the global cell and gene therapy market. The segment is expected to grow at a steady rate during the forecast period due to the increase in the target population and the rise in the number of countries preferring cell therapies in their patients. Increased therapeutic benefits are attracting several countries to invest in this technology and conduct a high number of clinical trials. However, the lack of advanced infrastructure in developing countries is hindering the growth of the segment.
In 2019, the oncology segment accounted for a share of over 40% in the global cell and gene therapy market. Oncology has been one of the targets of intense research for the gene therapy procedures & approach. More than 60% of on-going gene therapy clinical trials are targeting cancer. The segment is expected to grow at a promising rate on account of the high prevalence of cancer diseases, especially in low and middle-come countries. The market is growing at a double-digit CAGR, which is expected to help the segment as many cell and gene therapy for cancer are commercially available.
The dermatology application segment in the cell and gene therapy includes wound care management among patients. Vendors are focusing on the development and commercialization of advanced wound care products for the treatment of chronic and acute wounds, thereby increasing the growth of the wound care market. The increased pervasiveness of diabetics is increasing acute and chronic wounds, including surgical wounds, pressure ulcers, diabetic foot ulcers, and other wounds.
In 2019, the oncology segment accounted for a share of over 40% in the global cell and gene therapy market. Oncology has been one of the targets of intense research for the gene therapy procedures & approach. More than 60% of on-going gene therapy clinical trials are targeting cancer. The segment is expected to grow at a promising rate on account of the high prevalence of cancer diseases, especially in low and middle-come countries. The market is growing at a double-digit CAGR, which is expected to help the segment as many cell and gene therapy for cancer are commercially available.
The dermatology application segment in the cell and gene therapy includes wound care management among patients. Vendors are focusing on the development and commercialization of advanced wound care products for the treatment of chronic and acute wounds, thereby increasing the growth of the wound care market. The increased pervasiveness of diabetics is increasing acute and chronic wounds, including surgical wounds, pressure ulcers, diabetic foot ulcers, and other wounds.
Segmentation by Product
- Cell Therapy
- Gene Therapy
- Dermatology
- Musculoskeletal
- Oncology
- Genetic Disorders
- Others
- Hospitality
- Cancer Care Centers
- Wound Care Centers
- Ambulatory Surgical Centers
- Others
In 2019, North America accounted for a share of over 60% of the global cell and gene therapy market. There are more than 530 regenerative medicine companies, including cell and gene therapy manufacturing developers. The number of products approved in North America grew significantly in 2019, with developers filed for marketing authorization for 10+ regenerative medicines, many of which we expect to be approved in 2020. Within the next 1–2 years, the number of approved gene therapies is expected to double. The US and Canada are the major contributors to the cell and gene therapy market in North America. Regulatory bodies are supporting several investigational products, fast track approvals, RMAT designation for the faster approval of the product into the market. The alliance for regenerative medicine and Medicare and Medicaid is working together to bring the structured reimbursement channels for cell and gene therapies.
Segmentation by Geography
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Spain
- Italy
- APAC
- China
- Japan
- South Korea
- Australia
- India
- Latin America
- Brazil
- Mexico
- Middle East & Africa
- Saudi Arabia
- Turkey
- South Africa
- UAE
The global cell and gene therapy market is highly dynamic and characterized by the presence of several global, regional, and local vendors offering a wide range of therapies. Dendreon, Gilead Sciences, Novartis, Organogenesis, Osiris Therapeutics, Vericel, Amgen, and Spark Therapeutics are the leading players in the market with significant shares. Vendors such as NuVasive, APAC Biotech, Nipro, Orthocell, bluebird bio, J-TEC, and Terumo are the other prominent players in the market with a presence, especially in the cell therapy market. Most leading players are focusing on implementing strategies such as product launches and approvals, marketing and promotional activities, acquisitions, increased R&D investments, and strengthening their distribution networks to enhance their share and presence in the market.
Prominent Vendors
- Gilead Sciences
- Spark Therapeutics
- Novartis
- Organogenesis
- Amgen
- Osiris Therapeutics
- Dendreon
- Vericel
- Anterogen
- Tego Sciences
- Japan Tissue Engineering
- JCR Pharmaceuticals
- Medipost
- MolMed
- AVITA Medical
- CollPlant
- Biosolution
- Stempeutics Research
- Kolon Tissue Gene
- Orchard Therapeutics
- Sibiono GeneTech
- NuVasive
- Corestem
- Pharmicell
- Shanghai Sunway Biotech
- RMS Regenerative Medical System
- Takeda Pharmaceutical Company
- CHIESI Farmaceutici
- CO.DON
- AnGes
- GC Pharma
- Human Stem Cells Institute
- JW CreaGene
- APAC Biotech
- Nipro
- Terumo
- Orthocell
- bluebird bio
1. What is the cell and gene therapy market size and growth rate during the forecast period?
2. What are the factors impacting the growth of the cell and gene therapy market share?
3. How is the growth of the healthcare segment affecting the growth of the cell and gene therapy market?
4. Who are the leading vendors in the cell and gene therapy market, and what are their market shares?
5. Which product type/ end-user type/region is generating the largest revenue in the Asia Pacific region?
1 RESEARCH METHODOLOGY
2 RESEARCH OBJECTIVES
3 RESEARCH PROCESS
4 SCOPE & COVERAGE
4.1 Market Definition
4.1.1 Inclusions
4.1.2 Exclusions
4.2 Base Year
4.3 Scope of The Study
4.3.1 Market Segmentation by Product
4.3.2 Market Segmentation by Application
4.3.3 Market Segmentation by End-Users
4.3.4 Market Segmentation by Geography
5 REPORT ASSUMPTIONS & CAVEATS
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation
6 MARKET AT A GLANCE
7 INTRODUCTION
7.1 Overview
7.2 Cell and Gene Therapy: An Overview
8 MARKET OPPORTUNITIES & TRENDS
8.1 Increase in Strategic Acquisitions
8.2 Robust Cell & Gene Therapy Pipeline
8.3 Increased Funding for Cell & Gene Therapy Products
8.4 Expanding Applications for Cell & Gene Therapies
9 MARKET GROWTH ENABLERS
9.1 Increasing Pool of Target Patients
9.2 Product Launches & Approvals
9.3 Regulatory Support & Special Designation for Cell & Gene Therapy Products
9.4 Growing Demand for Car T-Cell Therapies
10 MARKET RESTRAINTS
10.1 High Cost of Cell and Gene Therapy
10.2 Limitations of Gene Therapy Products
10.3 Availability of Alternative Treatments & Withdrawal of Products
10.4 Manufacturing & Operational Challenges with Cell & Gene Therapy Products
10.5 Low Product Penetration in LMICS
11 MARKET LANDSCAPE
11.1 Market Overview
11.2 Market Size & Forecast
11.3 Five Forces Analysis
11.3.1 Threat of New Entrants
11.3.2 Bargaining Power of Suppliers
11.3.3 Bargaining Power of Buyers
11.3.4 Threat of Substitutes
11.3.5 Competitive Rivalry
12 BY PRODUCT
12.1 Market Snapshot & Growth Engine
12.2 Market Overview
12.3 Cell Therapy
12.3.1 Market Overview
12.3.2 Market Size & Forecast
12.4 Gene Therapy
12.4.1 Market Overview
12.4.2 Market Size & Forecast
13 BY APPLICATION
13.1 Market Snapshot & Growth Engine
13.2 Market Overview
13.3 Oncology
13.3.1 Market Overview
13.3.2 Market Size & Forecast
13.4 Dermatology
13.4.1 Market Overview
13.4.2 Market Size & Forecast
13.5 Musculoskeletal
13.5.1 Market Overview
13.5.2 Market Size & Forecast
13.6 Genetic Disorders
13.6.1 Market Overview
13.6.2 Market Size & Forecast
13.7 Others
13.7.1 Market Overview
13.7.2 Market Size & Forecast
14 BY END-USER
14.1 Market Snapshot & Growth Engine
14.2 Market Overview
14.3 Hospitals
14.3.1 Market Overview
14.3.2 Market Size & Forecast
14.4 Wound Care Centers
14.4.1 Market Overview
14.4.2 Market Size & Forecast
14.5 Cancer Care Centers
14.5.1 Market Overview
14.5.2 Market Size & Forecast
14.6 AMBULATORY SURGICAL CENTERS
14.6.1 Market Overview
14.6.2 Market Size & Forecast
14.7 OTHERS
14.7.1 Market Overview
14.7.2 Market Size & Forecast
15 BY GEOGRAPHY
15.1 Market Snapshot & Growth Engine
15.2 Geographic Overview
16 NORTH AMERICA
16.1 Market Overview
16.2 Market Size & Forecast
16.3 Key Countries
16.3.1 US: Market Size & Forecast
16.3.2 Canada: Market Size & Forecast
17 EUROPE
17.1 Market Overview
17.2 Market Size & Forecast
17.3 Key Countries
17.3.1 Germany: Market Size & Forecast
17.3.2 France: Market Size & Forecast
17.3.3 UK: Market Size & Forecast
17.3.4 Spain: Market Size & Forecast
17.3.5 Italy: Market Size & Forecast
18 APAC
18.1 Market Overview
18.2 Market Size & Forecast
18.3 Key Countries
18.3.1 Japan: Market Size & Forecast
18.3.2 China: Market Size & Forecast
18.3.3 South Korea: Market Size & Forecast
18.3.4 Australia: Market Size & Forecast
18.3.5 India: Market Size & Forecast
19 LATIN AMERICA
19.1 Market Overview
19.2 Market Size & Forecast
19.3 Key Countries
19.3.1 Brazil: Market Size & Forecast
19.3.2 Mexico: Market Size & Forecast
20 MIDDLE EAST & AFRICA
20.1 Market Overview
20.2 Market Size & Forecast
20.3 Key Countries
20.3.1 Turkey: Market Size & Forecast
20.3.2 Saudi Arabia: Market Size & Forecast
20.3.3 UAE: Market Size & Forecast
20.3.4 South Africa: Market Size & Forecast
21 COMPETITIVE LANDSCAPE
21.1 Competition Overview
21.2 Market Share Analysis
21.2.1 Gilead Sciences
21.2.2 Spark Therapeutics
21.2.3 Novartis
21.2.4 Amgen
21.2.5 Osiris Therapeutics
21.2.6 Denderon
21.2.7 Organogenesis
21.2.8 Vericel
22 KEY COMPANY PROFILES
22.1 Gilead Sciences
22.1.1 Business Overview
22.1.2 Product Offerings
22.1.3 Key Strategies
22.1.4 Key Strengths
22.1.5 Key Opportunities
22.2 Spark Therapeutics
22.2.1 Business Overview
22.2.2 Product Offerings
22.2.3 Key Strategies
22.2.4 Key Strengths
22.2.5 Key Opportunities
22.3 Novartis
22.3.1 Business Overview
22.3.2 Product Offerings
22.3.3 Key Strategies
22.3.4 Key Strengths
22.3.5 Key Opportunities
22.4 Organogenesis
22.4.1 Business Overview
22.4.2 Product Offerings
22.4.3 Key Strategies
22.4.4 Key Strengths
22.4.5 Key Opportunities
22.5 AMGEN
22.5.1 Business Overview
22.5.2 Product Offerings
22.5.3 Key Strategies
22.5.4 Key Strengths
22.5.5 Key Opportunities
22.6 Osiris Therapeutics
22.6.1 Business Overview
22.6.2 Product Offerings
22.6.3 Key Strategies
22.6.4 Key Strengths
22.6.5 Key Opportunities
22.7 Dendreon
22.7.1 Business Overview
22.7.2 Product Offerings
22.7.3 Key Strategies
22.7.4 Key Strengths
22.7.5 Key Opportunities
22.8 Vericel
22.8.1 Business Overview
22.8.2 Product Offerings
22.8.3 Key Strategies
22.8.4 Key Strengths
22.8.5 Key Opportunities
23 OTHER PROMINENT VENDORS
23.1 Anterogen
23.1.1 Business Overview
23.1.2 Product Offerings
23.2 Tego Sciences
23.2.1 Business Overview
23.2.2 Product Offerings
23.3 Japan Tissue Engineering (J-TEC)
23.3.1 Business Overview
23.3.2 Product Offerings
23.4 JCR Pharmaceuticals
23.4.1 Business Overview
23.4.2 Product Offerings
23.5 Medipost
23.5.1 Business Overview
23.5.2 Product Offerings
23.6 Molmed
23.6.1 Business Overview
23.6.2 Product Offerings
23.7 Avita Medical
23.7.1 Business Overview
23.7.2 Product Offerings
23.8 Collplant
23.8.1 Business Overview
23.8.2 Product Offerings
23.9 Biosolution
23.9.1 Business Overview
23.9.2 Product Offerings
23.10 Stempeutics Research
23.10.1 Business Overview
23.10.2 Product Offerings
23.11 Kolon Tissue Gene
23.11.1 Business Overview
23.11.2 Product Offerings
23.12 Orchard Therapeutics
23.12.1 Business Overview
23.12.2 Product Offerings
23.13 Sibiono Genetech
23.13.1 Business Overview
23.13.2 Product Offerings
23.14 Nuvasive
23.14.1 Business Overview
23.15 Corestem
23.15.1 Business Overview
23.16 Pharmicell
23.16.1 Business Overview
23.17 Shanghai Sunway Biotech
23.17.1 Business Overview
23.17.2 Product Offerings
23.18 RMS Regenerative Medical System
23.18.1 Business Overview
23.18.2 Product Offerings
23.19 Takeda Pharmaceutical Company
23.19.1 Business Overview
23.19.2 Product Offerings
23.20 Chiesi Farmaceutici
23.20.1 Business Overview
23.20.2 Product Offerings
23.21 CO.DON
23.21.1 Business Overview
23.21.2 Product Offerings
23.22 ANGES
23.22.1 Business Overview
23.22.2 Product Offerings
23.23 GC PHARMA
23.23.1 Business Overview
23.23.2 Product Offerings
23.24 Human Stem Cell Institute
23.24.1 Business Overview
23.25 JW CREAGENE
23.25.1 Business Overview
23.25.2 Product Offerings
23.26 APAC BIOTECH
23.26.1 Business Overview
23.26.2 Product Offerings
23.27 NIPRO
23.27.1 Business Overview
23.27.2 Product Offerings
23.28 TERUMO
23.28.1 Business Overview
23.28.2 Product Offerings
23.29 ORTHOCELL
23.29.1 Business Overview
23.29.2 Product Offerings
23.30 BLUEBIRD BIO
23.30.1 Business Overview
23.30.2 Product Offerings
24 REPORT SUMMARY
24.1 Key Takeaways
24.2 Strategic Recommendations
25 QUANTITATIVE SUMMARY
25.1 Market by Geography
25.2 Market by Therapy
25.3 Market by Aplications
25.4 Market by End-users
26 APPENDIX
26.1 Abbreviations
2 RESEARCH OBJECTIVES
3 RESEARCH PROCESS
4 SCOPE & COVERAGE
4.1 Market Definition
4.1.1 Inclusions
4.1.2 Exclusions
4.2 Base Year
4.3 Scope of The Study
4.3.1 Market Segmentation by Product
4.3.2 Market Segmentation by Application
4.3.3 Market Segmentation by End-Users
4.3.4 Market Segmentation by Geography
5 REPORT ASSUMPTIONS & CAVEATS
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation
6 MARKET AT A GLANCE
7 INTRODUCTION
7.1 Overview
7.2 Cell and Gene Therapy: An Overview
8 MARKET OPPORTUNITIES & TRENDS
8.1 Increase in Strategic Acquisitions
8.2 Robust Cell & Gene Therapy Pipeline
8.3 Increased Funding for Cell & Gene Therapy Products
8.4 Expanding Applications for Cell & Gene Therapies
9 MARKET GROWTH ENABLERS
9.1 Increasing Pool of Target Patients
9.2 Product Launches & Approvals
9.3 Regulatory Support & Special Designation for Cell & Gene Therapy Products
9.4 Growing Demand for Car T-Cell Therapies
10 MARKET RESTRAINTS
10.1 High Cost of Cell and Gene Therapy
10.2 Limitations of Gene Therapy Products
10.3 Availability of Alternative Treatments & Withdrawal of Products
10.4 Manufacturing & Operational Challenges with Cell & Gene Therapy Products
10.5 Low Product Penetration in LMICS
11 MARKET LANDSCAPE
11.1 Market Overview
11.2 Market Size & Forecast
11.3 Five Forces Analysis
11.3.1 Threat of New Entrants
11.3.2 Bargaining Power of Suppliers
11.3.3 Bargaining Power of Buyers
11.3.4 Threat of Substitutes
11.3.5 Competitive Rivalry
12 BY PRODUCT
12.1 Market Snapshot & Growth Engine
12.2 Market Overview
12.3 Cell Therapy
12.3.1 Market Overview
12.3.2 Market Size & Forecast
12.4 Gene Therapy
12.4.1 Market Overview
12.4.2 Market Size & Forecast
13 BY APPLICATION
13.1 Market Snapshot & Growth Engine
13.2 Market Overview
13.3 Oncology
13.3.1 Market Overview
13.3.2 Market Size & Forecast
13.4 Dermatology
13.4.1 Market Overview
13.4.2 Market Size & Forecast
13.5 Musculoskeletal
13.5.1 Market Overview
13.5.2 Market Size & Forecast
13.6 Genetic Disorders
13.6.1 Market Overview
13.6.2 Market Size & Forecast
13.7 Others
13.7.1 Market Overview
13.7.2 Market Size & Forecast
14 BY END-USER
14.1 Market Snapshot & Growth Engine
14.2 Market Overview
14.3 Hospitals
14.3.1 Market Overview
14.3.2 Market Size & Forecast
14.4 Wound Care Centers
14.4.1 Market Overview
14.4.2 Market Size & Forecast
14.5 Cancer Care Centers
14.5.1 Market Overview
14.5.2 Market Size & Forecast
14.6 AMBULATORY SURGICAL CENTERS
14.6.1 Market Overview
14.6.2 Market Size & Forecast
14.7 OTHERS
14.7.1 Market Overview
14.7.2 Market Size & Forecast
15 BY GEOGRAPHY
15.1 Market Snapshot & Growth Engine
15.2 Geographic Overview
16 NORTH AMERICA
16.1 Market Overview
16.2 Market Size & Forecast
16.3 Key Countries
16.3.1 US: Market Size & Forecast
16.3.2 Canada: Market Size & Forecast
17 EUROPE
17.1 Market Overview
17.2 Market Size & Forecast
17.3 Key Countries
17.3.1 Germany: Market Size & Forecast
17.3.2 France: Market Size & Forecast
17.3.3 UK: Market Size & Forecast
17.3.4 Spain: Market Size & Forecast
17.3.5 Italy: Market Size & Forecast
18 APAC
18.1 Market Overview
18.2 Market Size & Forecast
18.3 Key Countries
18.3.1 Japan: Market Size & Forecast
18.3.2 China: Market Size & Forecast
18.3.3 South Korea: Market Size & Forecast
18.3.4 Australia: Market Size & Forecast
18.3.5 India: Market Size & Forecast
19 LATIN AMERICA
19.1 Market Overview
19.2 Market Size & Forecast
19.3 Key Countries
19.3.1 Brazil: Market Size & Forecast
19.3.2 Mexico: Market Size & Forecast
20 MIDDLE EAST & AFRICA
20.1 Market Overview
20.2 Market Size & Forecast
20.3 Key Countries
20.3.1 Turkey: Market Size & Forecast
20.3.2 Saudi Arabia: Market Size & Forecast
20.3.3 UAE: Market Size & Forecast
20.3.4 South Africa: Market Size & Forecast
21 COMPETITIVE LANDSCAPE
21.1 Competition Overview
21.2 Market Share Analysis
21.2.1 Gilead Sciences
21.2.2 Spark Therapeutics
21.2.3 Novartis
21.2.4 Amgen
21.2.5 Osiris Therapeutics
21.2.6 Denderon
21.2.7 Organogenesis
21.2.8 Vericel
22 KEY COMPANY PROFILES
22.1 Gilead Sciences
22.1.1 Business Overview
22.1.2 Product Offerings
22.1.3 Key Strategies
22.1.4 Key Strengths
22.1.5 Key Opportunities
22.2 Spark Therapeutics
22.2.1 Business Overview
22.2.2 Product Offerings
22.2.3 Key Strategies
22.2.4 Key Strengths
22.2.5 Key Opportunities
22.3 Novartis
22.3.1 Business Overview
22.3.2 Product Offerings
22.3.3 Key Strategies
22.3.4 Key Strengths
22.3.5 Key Opportunities
22.4 Organogenesis
22.4.1 Business Overview
22.4.2 Product Offerings
22.4.3 Key Strategies
22.4.4 Key Strengths
22.4.5 Key Opportunities
22.5 AMGEN
22.5.1 Business Overview
22.5.2 Product Offerings
22.5.3 Key Strategies
22.5.4 Key Strengths
22.5.5 Key Opportunities
22.6 Osiris Therapeutics
22.6.1 Business Overview
22.6.2 Product Offerings
22.6.3 Key Strategies
22.6.4 Key Strengths
22.6.5 Key Opportunities
22.7 Dendreon
22.7.1 Business Overview
22.7.2 Product Offerings
22.7.3 Key Strategies
22.7.4 Key Strengths
22.7.5 Key Opportunities
22.8 Vericel
22.8.1 Business Overview
22.8.2 Product Offerings
22.8.3 Key Strategies
22.8.4 Key Strengths
22.8.5 Key Opportunities
23 OTHER PROMINENT VENDORS
23.1 Anterogen
23.1.1 Business Overview
23.1.2 Product Offerings
23.2 Tego Sciences
23.2.1 Business Overview
23.2.2 Product Offerings
23.3 Japan Tissue Engineering (J-TEC)
23.3.1 Business Overview
23.3.2 Product Offerings
23.4 JCR Pharmaceuticals
23.4.1 Business Overview
23.4.2 Product Offerings
23.5 Medipost
23.5.1 Business Overview
23.5.2 Product Offerings
23.6 Molmed
23.6.1 Business Overview
23.6.2 Product Offerings
23.7 Avita Medical
23.7.1 Business Overview
23.7.2 Product Offerings
23.8 Collplant
23.8.1 Business Overview
23.8.2 Product Offerings
23.9 Biosolution
23.9.1 Business Overview
23.9.2 Product Offerings
23.10 Stempeutics Research
23.10.1 Business Overview
23.10.2 Product Offerings
23.11 Kolon Tissue Gene
23.11.1 Business Overview
23.11.2 Product Offerings
23.12 Orchard Therapeutics
23.12.1 Business Overview
23.12.2 Product Offerings
23.13 Sibiono Genetech
23.13.1 Business Overview
23.13.2 Product Offerings
23.14 Nuvasive
23.14.1 Business Overview
23.15 Corestem
23.15.1 Business Overview
23.16 Pharmicell
23.16.1 Business Overview
23.17 Shanghai Sunway Biotech
23.17.1 Business Overview
23.17.2 Product Offerings
23.18 RMS Regenerative Medical System
23.18.1 Business Overview
23.18.2 Product Offerings
23.19 Takeda Pharmaceutical Company
23.19.1 Business Overview
23.19.2 Product Offerings
23.20 Chiesi Farmaceutici
23.20.1 Business Overview
23.20.2 Product Offerings
23.21 CO.DON
23.21.1 Business Overview
23.21.2 Product Offerings
23.22 ANGES
23.22.1 Business Overview
23.22.2 Product Offerings
23.23 GC PHARMA
23.23.1 Business Overview
23.23.2 Product Offerings
23.24 Human Stem Cell Institute
23.24.1 Business Overview
23.25 JW CREAGENE
23.25.1 Business Overview
23.25.2 Product Offerings
23.26 APAC BIOTECH
23.26.1 Business Overview
23.26.2 Product Offerings
23.27 NIPRO
23.27.1 Business Overview
23.27.2 Product Offerings
23.28 TERUMO
23.28.1 Business Overview
23.28.2 Product Offerings
23.29 ORTHOCELL
23.29.1 Business Overview
23.29.2 Product Offerings
23.30 BLUEBIRD BIO
23.30.1 Business Overview
23.30.2 Product Offerings
24 REPORT SUMMARY
24.1 Key Takeaways
24.2 Strategic Recommendations
25 QUANTITATIVE SUMMARY
25.1 Market by Geography
25.2 Market by Therapy
25.3 Market by Aplications
25.4 Market by End-users
26 APPENDIX
26.1 Abbreviations
LIST OF EXHIBITS
Exhibit 1 Segmentation of Global Cell & Gene Therapy Market
Exhibit 2 Market Size Calculation Approach 2019
Exhibit 3 Regenerative Medicine Total Global Financings 2015-2019 ($ billion)
Exhibit 4 Impact of Increase in Strategic Acquisitions
Exhibit 5 Total Regenerative Medicine M&A Transactions 2016–2018 ($ billion)
Exhibit 6 Recent Strategic Acquisitions in Global Cell & Gene Therapy Market
Exhibit 7 Impact of Robust Cell & Gene Therapy Pipeline
Exhibit 8 Impact of Increased Funding for Cell & Gene Therapy Products
Exhibit 9 Global Funding for Cell & Gene Therapy Products 2017-2019 ($ billion)
Exhibit 10 Companies Involved in Regenerative Medicine R&D Activities 2017 & 2018
Exhibit 11 Impact of Expanding Applications for Cell & Gene Therapies
Exhibit 12 Impact of Increasing Pool of Target Population
Exhibit 13 Elderly Population in Selected Countries (2018)
Exhibit 14 Impact of Product Launches & Approvals
Exhibit 15 Impact of Regulatory Support & Special Designation for Cell & Gene Therapy Products
Exhibit 16 Impact of Growing Demand for CAR T-Cell Therapies
Exhibit 17 Yescarta & Kymriah Revenues 2019
Exhibit 18 Comparison of Yescarta & Kymriah Revenues 2018 vs 2019
Exhibit 19 Number of CAR T Cell Therapies in Clinical Trials January 2018
Exhibit 20 Major Vendors Engaged in Development of CAR T-Cell Therapies
Exhibit 21 Impact of High Cost of Cell & Gene Therapy
Exhibit 22 Cost of Select Marketed Cell & Gene Therapy Products (Lakhs)
Exhibit 23 Impact of Limitations of Gene Therapy Products
Exhibit 24 Impact of Availability of Alternative Treatments & Withdrawal of Products
Exhibit 25 Impact of Manufacturing & Operational Challenges with Cell & Gene Therapy Products
Exhibit 26 Challenges Associated with Cell & Gene Therapies for Vendors
Exhibit 27 Impact of Low Product Penetration in LMICs
Exhibit 28 Global Cell & Gene Therapy Market 2019–2025 ($ million)
Exhibit 29 Global Cell & Gene Therapy Market by Product: 2019 & 2025 percentage share comparison
Exhibit 30 Global Cell & Gene Therapy Market by Application: 2019 & 2025 percentage share comparison
Exhibit 31 Global Cell & Gene Therapy Market by End-users: 2019 & 2025 percentage share comparison
Exhibit 32 Global Cell & Gene Therapy Market by Geography: 2019 & 2025 percentage share comparison
Exhibit 33 Five Forces Analysis 2019
Exhibit 34 Incremental Growth by Product 2019 & 2025
Exhibit 35 Global Cell & Gene Therapy Market Segmentation by Product
Exhibit 36 Global Cell & Gene Therapy Market by Therapy: Incremental Growth
Exhibit 37 Global Cell & Gene Therapy Market by Therapy: Absolute Growth
Exhibit 38 Global Cell & Gene Therapy Market by Cell Therapy: Incremental Growth & Absolute Growth Comparison
Exhibit 39 Global Cell Therapy Market 2019–2025 ($ million)
Exhibit 40 Global Cell & Gene Therapy Market by Gene Therapy: Incremental Growth & Absolute Growth Comparison
Exhibit 41 Global Gene Therapy Market 2019–2025 ($ million)
Exhibit 42 Incremental Growth by Application 2019 & 2025
Exhibit 43 Global Cell & Gene Therapy Market by Application 2019
Exhibit 44 Global Cell & Gene Therapy Market by Application: Incremental Growth
Exhibit 45 Global Cell & Gene Therapy Market by Application: Absolute Growth
Exhibit 46 Global Incidence & Mortality of Most Common Cancer Cases (2018)
Exhibit 47 Major Cell & Gene Therapy Products Available for Cancer
Exhibit 48 Global Cell & Gene Therapy Market by Oncology: Incremental Growth & Absolute Growth Comparison
Exhibit 49 Global Oncology Cell & Gene Therapy Market 2019–2025 ($ million)
Exhibit 50 Distribution of Wound Types
Exhibit 51 Global Cell & Gene Therapy Market by Dermatology: Incremental Growth & Absolute Growth Comparison
Exhibit 52 Global Dermatology Cell & Gene Therapy Market 2019–2025 ($ million)
Exhibit 53 Global Cell & Gene Therapy Market by Musculoskeletal Disorders: Incremental Growth & Absolute Growth Comparison
Exhibit 54 Global Musculoskeletal Cell & Gene Therapy Market 2019–2025 ($ million)
Exhibit 55 Zolgensma, Luxturna, and Strimvelis Revenue 2019 ($ million)
Exhibit 56 Global Cell & Gene Therapy Market by Genetic Disorders: Incremental Growth & Absolute Growth Comparison
Exhibit 57 Global Genetic Disorders Cell &Gene Therapy Market 2019–2025 ($ million)
Exhibit 58 Global Cell & Gene Therapy Market by Others: Incremental Growth & Absolute Growth Comparison
Exhibit 59 Global Other Cell & Gene Therapy Market 2019–2025 ($ million)
Exhibit 60 Incremental Growth by End-User 2019 & 2025
Exhibit 61 Global Cell & Gene Therapy Market by End-Users
Exhibit 62 Global Cell & Gene Therapy Market by End-Users: Incremental Growth
Exhibit 63 Global Cell & Gene Therapy Market by End-Users: Absolute Growth
Exhibit 64 Global Cell & Gene Therapy Market by Hospitals: Incremental Growth & Absolute Growth Comparison
Exhibit 65 Global Hospitals Cell & Gene Therapy Market 2019–2025 ($ million)
Exhibit 66 Global Cell & Gene Therapy Market by Wound Care Centers: Incremental Growth & Absolute Growth Comparison
Exhibit 67 Global Wound Care Center Cell & Gene Therapy Market 2019–2025 ($ million)
Exhibit 68 Global Cell & Gene Therapy Market by Cancer Care Centers: Incremental Growth & Absolute Growth Comparison
Exhibit 69 Global Cancer Care Center Cell & Gene Therapy Market 2019–2025 ($ million)
Exhibit 70 Global Cell & Gene Therapy Market by ASCs: Incremental Growth & Absolute Growth Comparison
Exhibit 71 Global ASC Cell & Gene Therapy Market 2019–2025 ($ million)
Exhibit 72 Global Cell & Gene Therapy Market by Other End-Users: Incremental Growth & Absolute Growth Comparison
Exhibit 73 Global Other End-Users Cell & Gene Therapy Market 2019–2025 ($ million)
Exhibit 74 Incremental Growth by Geography 2019 & 2025
Exhibit 75 Global Cell & Gene Therapy Market by Geography
Exhibit 76 Global Cell & Gene Therapy Market by Geography: Incremental Growth
Exhibit 77 Global Cell & Gene Therapy Market by Geography: Absolute Growth
Exhibit 78 Cell & Gene Therapy Market in North America: Key Countries ($ Million)
Exhibit 79 Cell & Gene Therapy Market in North America: Incremental Growth & Absolute Growth Comparison
Exhibit 80 Cell & Gene Therapy Market in North America 2019–2025 ($ million)
Exhibit 81 Incremental Growth in North America 2019 & 2025
Exhibit 82 Cell & Gene Therapy Market in US 2019–2025 ($ million)
Exhibit 83 Yescarta Revenue in US 2018 & 2019 ($ million)
Exhibit 84 Cell & Gene Therapy Market in Canada 2019–2025 ($ million)
Exhibit 85 Development & Commercialization of Cell & Gene Therapy Products in Europe
Exhibit 86 Cell & Gene Therapy Market in Europe: Key Countries ($ Million)
Exhibit 87 Cell & Gene Therapy Market in Europe: Incremental Growth & Absolute Growth Comparison
Exhibit 88 Cell & Gene Therapy Market in Europe 2019–2025 ($ million)
Exhibit 89 Incremental Growth in Europe 2019 & 2025
Exhibit 90 Cell & Gene Therapy Market in Germany 2019–2025 ($ million)
Exhibit 91 Cell & Gene Therapy Market in France 2019–2025 ($ million)
Exhibit 92 Cell & Gene Therapy Market in UK 2019–2025 ($ million)
Exhibit 93 Cell & Gene Therapy Market in Spain 2019–2025 ($ million)
Exhibit 94 Cell & Gene Therapy Market in Italy 2019–2025 ($ million)
Exhibit 95 Cell & Gene Therapy Market in APAC: Key Countries ($ Million)
Exhibit 96 Cell & Gene Therapy Market in APAC: Incremental Growth & Absolute Growth Comparison
Exhibit 97 Cell & Gene Therapy Market in APAC 2019–2025 ($ million)
Exhibit 98 Incremental Growth in APAC 2019 & 2025
Exhibit 99 Cell & Gene Therapy Market in Japan 2019–2025 ($ million)
Exhibit 100 Cell & Gene Therapy Market in China 2019–2025 ($ million)
Exhibit 101 Cell & Gene Therapy Market in South Korea 2019–2025 ($ million)
Exhibit 102 Cell & Gene Therapy Market in Australia 2019–2025 ($ million)
Exhibit 103 Cell & Gene Therapy Market in India 2019–2025 ($ million)
Exhibit 104 Cell & Gene Therapy Market in Latin America: Incremental Growth & Absolute Growth Comparison
Exhibit 105 Cell & Gene Therapy Market in Latin America: Key Countries ($ million)
Exhibit 106 Cell & Gene Therapy Market in Latin America 2019–2025 ($ million)
Exhibit 107 Incremental Growth in Latin America 2019 & 2025
Exhibit 108 Cell & Gene Therapy Market in Brazil 2019–2025 ($ million)
Exhibit 109 Cell & Gene Therapy Market in Mexico 2019–2025 ($ million)
Exhibit 110 Cell & Gene Therapy Market in MEA: Key Countries ($ million)
Exhibit 111 Cell & Gene Therapy Market in MEA: Incremental Growth & Absolute Growth Comparison
Exhibit 112 Cell & Gene Therapy Market in MEA 2019–2025 ($ million)
Exhibit 113 Incremental Growth in MEA 2019 & 2025
Exhibit 114 Cell & Gene Therapy Market in Turkey 2019–2025 ($ million)
Exhibit 115 Cell & Gene Therapy Market in Saudi Arabia 2019–2025 ($ million)
Exhibit 116 Cell & Gene Therapy Market in UAE 2019–2025 ($ million)
Exhibit 117 Cell & Gene Therapy Market in South Africa 2019–2025 ($ million)
Exhibit 118 Global Cell and Gene Therapy Market: Vendors Ranking 2019
Exhibit 119 Global Gene Therapy Market: Vendors Ranking 2019
Exhibit 120 Global Cell Therapy Market: Vendors Ranking 2019
Exhibit 121 Yescarta Revenue 2017-2019 ($ million)
Exhibit 122 Novartis Kymriah & Zolgensma Revenue 2019 ($ million)
Exhibit 123 Osiris Therapeutics Grafix & BIO4 2018 & 2019 Revenue Comparison
Exhibit 124 Gilead Sciences Revenue 2017–2019 ($ billion)
Exhibit 125 Gilead Sciences Research & Development Expenses 2017–2019 ($ billion)
Exhibit 126 LUXTURNA Revenue 2018 ($ million)
Exhibit 127 Spark Therapeutics Research & Development Expenses 2017–2019 ($ million)
Exhibit 128 Novartis Revenue 2017–2019 ($ billion)
Exhibit 129 Novartis Segment Revenue 2019 ($ billion)
Exhibit 130 Regional Revenue Breakup – 2019 ($ million)
Exhibit 131 Organogenesis Revenue 2018–2019 ($ billion)
Exhibit 132 Organogenesis R&D Expenditure 2018–2019 ($ billion)
Exhibit 133 Amgen Revenue 2017–2019 ($ billion)
Exhibit 134 Amgen Research & Development Expenses 2017–2019 ($ billion)
Exhibit 135 Osiris Therapeutics Revenue 2017–2019 ($ billion)
Exhibit 136 Vericel Revenue 2017–2019 ($ million)
Exhibit 137 Vericel R&D Expenditure 2017–2019 ($ Thousands)
Exhibit 1 Segmentation of Global Cell & Gene Therapy Market
Exhibit 2 Market Size Calculation Approach 2019
Exhibit 3 Regenerative Medicine Total Global Financings 2015-2019 ($ billion)
Exhibit 4 Impact of Increase in Strategic Acquisitions
Exhibit 5 Total Regenerative Medicine M&A Transactions 2016–2018 ($ billion)
Exhibit 6 Recent Strategic Acquisitions in Global Cell & Gene Therapy Market
Exhibit 7 Impact of Robust Cell & Gene Therapy Pipeline
Exhibit 8 Impact of Increased Funding for Cell & Gene Therapy Products
Exhibit 9 Global Funding for Cell & Gene Therapy Products 2017-2019 ($ billion)
Exhibit 10 Companies Involved in Regenerative Medicine R&D Activities 2017 & 2018
Exhibit 11 Impact of Expanding Applications for Cell & Gene Therapies
Exhibit 12 Impact of Increasing Pool of Target Population
Exhibit 13 Elderly Population in Selected Countries (2018)
Exhibit 14 Impact of Product Launches & Approvals
Exhibit 15 Impact of Regulatory Support & Special Designation for Cell & Gene Therapy Products
Exhibit 16 Impact of Growing Demand for CAR T-Cell Therapies
Exhibit 17 Yescarta & Kymriah Revenues 2019
Exhibit 18 Comparison of Yescarta & Kymriah Revenues 2018 vs 2019
Exhibit 19 Number of CAR T Cell Therapies in Clinical Trials January 2018
Exhibit 20 Major Vendors Engaged in Development of CAR T-Cell Therapies
Exhibit 21 Impact of High Cost of Cell & Gene Therapy
Exhibit 22 Cost of Select Marketed Cell & Gene Therapy Products (Lakhs)
Exhibit 23 Impact of Limitations of Gene Therapy Products
Exhibit 24 Impact of Availability of Alternative Treatments & Withdrawal of Products
Exhibit 25 Impact of Manufacturing & Operational Challenges with Cell & Gene Therapy Products
Exhibit 26 Challenges Associated with Cell & Gene Therapies for Vendors
Exhibit 27 Impact of Low Product Penetration in LMICs
Exhibit 28 Global Cell & Gene Therapy Market 2019–2025 ($ million)
Exhibit 29 Global Cell & Gene Therapy Market by Product: 2019 & 2025 percentage share comparison
Exhibit 30 Global Cell & Gene Therapy Market by Application: 2019 & 2025 percentage share comparison
Exhibit 31 Global Cell & Gene Therapy Market by End-users: 2019 & 2025 percentage share comparison
Exhibit 32 Global Cell & Gene Therapy Market by Geography: 2019 & 2025 percentage share comparison
Exhibit 33 Five Forces Analysis 2019
Exhibit 34 Incremental Growth by Product 2019 & 2025
Exhibit 35 Global Cell & Gene Therapy Market Segmentation by Product
Exhibit 36 Global Cell & Gene Therapy Market by Therapy: Incremental Growth
Exhibit 37 Global Cell & Gene Therapy Market by Therapy: Absolute Growth
Exhibit 38 Global Cell & Gene Therapy Market by Cell Therapy: Incremental Growth & Absolute Growth Comparison
Exhibit 39 Global Cell Therapy Market 2019–2025 ($ million)
Exhibit 40 Global Cell & Gene Therapy Market by Gene Therapy: Incremental Growth & Absolute Growth Comparison
Exhibit 41 Global Gene Therapy Market 2019–2025 ($ million)
Exhibit 42 Incremental Growth by Application 2019 & 2025
Exhibit 43 Global Cell & Gene Therapy Market by Application 2019
Exhibit 44 Global Cell & Gene Therapy Market by Application: Incremental Growth
Exhibit 45 Global Cell & Gene Therapy Market by Application: Absolute Growth
Exhibit 46 Global Incidence & Mortality of Most Common Cancer Cases (2018)
Exhibit 47 Major Cell & Gene Therapy Products Available for Cancer
Exhibit 48 Global Cell & Gene Therapy Market by Oncology: Incremental Growth & Absolute Growth Comparison
Exhibit 49 Global Oncology Cell & Gene Therapy Market 2019–2025 ($ million)
Exhibit 50 Distribution of Wound Types
Exhibit 51 Global Cell & Gene Therapy Market by Dermatology: Incremental Growth & Absolute Growth Comparison
Exhibit 52 Global Dermatology Cell & Gene Therapy Market 2019–2025 ($ million)
Exhibit 53 Global Cell & Gene Therapy Market by Musculoskeletal Disorders: Incremental Growth & Absolute Growth Comparison
Exhibit 54 Global Musculoskeletal Cell & Gene Therapy Market 2019–2025 ($ million)
Exhibit 55 Zolgensma, Luxturna, and Strimvelis Revenue 2019 ($ million)
Exhibit 56 Global Cell & Gene Therapy Market by Genetic Disorders: Incremental Growth & Absolute Growth Comparison
Exhibit 57 Global Genetic Disorders Cell &Gene Therapy Market 2019–2025 ($ million)
Exhibit 58 Global Cell & Gene Therapy Market by Others: Incremental Growth & Absolute Growth Comparison
Exhibit 59 Global Other Cell & Gene Therapy Market 2019–2025 ($ million)
Exhibit 60 Incremental Growth by End-User 2019 & 2025
Exhibit 61 Global Cell & Gene Therapy Market by End-Users
Exhibit 62 Global Cell & Gene Therapy Market by End-Users: Incremental Growth
Exhibit 63 Global Cell & Gene Therapy Market by End-Users: Absolute Growth
Exhibit 64 Global Cell & Gene Therapy Market by Hospitals: Incremental Growth & Absolute Growth Comparison
Exhibit 65 Global Hospitals Cell & Gene Therapy Market 2019–2025 ($ million)
Exhibit 66 Global Cell & Gene Therapy Market by Wound Care Centers: Incremental Growth & Absolute Growth Comparison
Exhibit 67 Global Wound Care Center Cell & Gene Therapy Market 2019–2025 ($ million)
Exhibit 68 Global Cell & Gene Therapy Market by Cancer Care Centers: Incremental Growth & Absolute Growth Comparison
Exhibit 69 Global Cancer Care Center Cell & Gene Therapy Market 2019–2025 ($ million)
Exhibit 70 Global Cell & Gene Therapy Market by ASCs: Incremental Growth & Absolute Growth Comparison
Exhibit 71 Global ASC Cell & Gene Therapy Market 2019–2025 ($ million)
Exhibit 72 Global Cell & Gene Therapy Market by Other End-Users: Incremental Growth & Absolute Growth Comparison
Exhibit 73 Global Other End-Users Cell & Gene Therapy Market 2019–2025 ($ million)
Exhibit 74 Incremental Growth by Geography 2019 & 2025
Exhibit 75 Global Cell & Gene Therapy Market by Geography
Exhibit 76 Global Cell & Gene Therapy Market by Geography: Incremental Growth
Exhibit 77 Global Cell & Gene Therapy Market by Geography: Absolute Growth
Exhibit 78 Cell & Gene Therapy Market in North America: Key Countries ($ Million)
Exhibit 79 Cell & Gene Therapy Market in North America: Incremental Growth & Absolute Growth Comparison
Exhibit 80 Cell & Gene Therapy Market in North America 2019–2025 ($ million)
Exhibit 81 Incremental Growth in North America 2019 & 2025
Exhibit 82 Cell & Gene Therapy Market in US 2019–2025 ($ million)
Exhibit 83 Yescarta Revenue in US 2018 & 2019 ($ million)
Exhibit 84 Cell & Gene Therapy Market in Canada 2019–2025 ($ million)
Exhibit 85 Development & Commercialization of Cell & Gene Therapy Products in Europe
Exhibit 86 Cell & Gene Therapy Market in Europe: Key Countries ($ Million)
Exhibit 87 Cell & Gene Therapy Market in Europe: Incremental Growth & Absolute Growth Comparison
Exhibit 88 Cell & Gene Therapy Market in Europe 2019–2025 ($ million)
Exhibit 89 Incremental Growth in Europe 2019 & 2025
Exhibit 90 Cell & Gene Therapy Market in Germany 2019–2025 ($ million)
Exhibit 91 Cell & Gene Therapy Market in France 2019–2025 ($ million)
Exhibit 92 Cell & Gene Therapy Market in UK 2019–2025 ($ million)
Exhibit 93 Cell & Gene Therapy Market in Spain 2019–2025 ($ million)
Exhibit 94 Cell & Gene Therapy Market in Italy 2019–2025 ($ million)
Exhibit 95 Cell & Gene Therapy Market in APAC: Key Countries ($ Million)
Exhibit 96 Cell & Gene Therapy Market in APAC: Incremental Growth & Absolute Growth Comparison
Exhibit 97 Cell & Gene Therapy Market in APAC 2019–2025 ($ million)
Exhibit 98 Incremental Growth in APAC 2019 & 2025
Exhibit 99 Cell & Gene Therapy Market in Japan 2019–2025 ($ million)
Exhibit 100 Cell & Gene Therapy Market in China 2019–2025 ($ million)
Exhibit 101 Cell & Gene Therapy Market in South Korea 2019–2025 ($ million)
Exhibit 102 Cell & Gene Therapy Market in Australia 2019–2025 ($ million)
Exhibit 103 Cell & Gene Therapy Market in India 2019–2025 ($ million)
Exhibit 104 Cell & Gene Therapy Market in Latin America: Incremental Growth & Absolute Growth Comparison
Exhibit 105 Cell & Gene Therapy Market in Latin America: Key Countries ($ million)
Exhibit 106 Cell & Gene Therapy Market in Latin America 2019–2025 ($ million)
Exhibit 107 Incremental Growth in Latin America 2019 & 2025
Exhibit 108 Cell & Gene Therapy Market in Brazil 2019–2025 ($ million)
Exhibit 109 Cell & Gene Therapy Market in Mexico 2019–2025 ($ million)
Exhibit 110 Cell & Gene Therapy Market in MEA: Key Countries ($ million)
Exhibit 111 Cell & Gene Therapy Market in MEA: Incremental Growth & Absolute Growth Comparison
Exhibit 112 Cell & Gene Therapy Market in MEA 2019–2025 ($ million)
Exhibit 113 Incremental Growth in MEA 2019 & 2025
Exhibit 114 Cell & Gene Therapy Market in Turkey 2019–2025 ($ million)
Exhibit 115 Cell & Gene Therapy Market in Saudi Arabia 2019–2025 ($ million)
Exhibit 116 Cell & Gene Therapy Market in UAE 2019–2025 ($ million)
Exhibit 117 Cell & Gene Therapy Market in South Africa 2019–2025 ($ million)
Exhibit 118 Global Cell and Gene Therapy Market: Vendors Ranking 2019
Exhibit 119 Global Gene Therapy Market: Vendors Ranking 2019
Exhibit 120 Global Cell Therapy Market: Vendors Ranking 2019
Exhibit 121 Yescarta Revenue 2017-2019 ($ million)
Exhibit 122 Novartis Kymriah & Zolgensma Revenue 2019 ($ million)
Exhibit 123 Osiris Therapeutics Grafix & BIO4 2018 & 2019 Revenue Comparison
Exhibit 124 Gilead Sciences Revenue 2017–2019 ($ billion)
Exhibit 125 Gilead Sciences Research & Development Expenses 2017–2019 ($ billion)
Exhibit 126 LUXTURNA Revenue 2018 ($ million)
Exhibit 127 Spark Therapeutics Research & Development Expenses 2017–2019 ($ million)
Exhibit 128 Novartis Revenue 2017–2019 ($ billion)
Exhibit 129 Novartis Segment Revenue 2019 ($ billion)
Exhibit 130 Regional Revenue Breakup – 2019 ($ million)
Exhibit 131 Organogenesis Revenue 2018–2019 ($ billion)
Exhibit 132 Organogenesis R&D Expenditure 2018–2019 ($ billion)
Exhibit 133 Amgen Revenue 2017–2019 ($ billion)
Exhibit 134 Amgen Research & Development Expenses 2017–2019 ($ billion)
Exhibit 135 Osiris Therapeutics Revenue 2017–2019 ($ billion)
Exhibit 136 Vericel Revenue 2017–2019 ($ million)
Exhibit 137 Vericel R&D Expenditure 2017–2019 ($ Thousands)
LIST OF TABLES
Table 1 Key Caveats
Table 2 Currency Conversion 2013?2019
Table 3 Gene Therapies in Significant Stages of Clinical Pipeline
Table 4 Cell & Gene Therapy Products with Expanding Applications
Table 5 Product Approvals &Launch Details
Table 6 List of Products Received RMAT Designation in 2019
Table 7 List of Products Received PRIME Designation in 2019
Table 8 CAR T-Cell Investigational Products
Table 9 Cost of Kymriah in Different Regions
Table 10 Top Cancer Care Centers Across the Globe
Table 11 Major Cell & Gene Therapy Products Approved Recently in Europe
Table 12 Gilead Sciences: Major Product Offerings
Table 13 Spark Therapeutics: Major Product Offerings
Table 14 Novartis: Major Product Offerings
Table 15 Organogenesis: Major Product Offerings
Table 16 Amgen: Major Product Offerings
Table 17 Osiris Therapeutics: Major Product Offerings
Table 18 Dendreon: Major Product Offerings
Table 19 Vericel: Major Product Offerings
Table 20 Anterogen: Major Product Offerings
Table 21 Tego Sciences: Major Product Offerings
Table 22 JAPAN TISSUE ENGINEERING (J-TEC): Major Product Offerings
Table 23 JCR Pharmaceuticals: Major Product Offerings
Table 24 Medipost: Major Product Offerings
Table 25 MolMed: Major Product Offerings
Table 26 Avita Medical: Major Product Offerings
Table 27 Collplant: Major Product Offerings
Table 28 Biosolution: Major Product Offerings
Table 29 Stempeutics Research: Major Product Offerings
Table 30 Kolon Tissue Gene: Major Product Offerings
Table 31 Orchard Therapeutics: Major Product Offerings
Table 32 Sibiono GeneTech: Major Product Offerings
Table 33 Shanghai Sunway Biotech: Major Product Offerings
Table 34 RMS Regenerative Medical System: Major Product Offerings
Table 35 Takeda Pharmaceutical Company: Major Product Offerings
Table 36 CHIESI Farmaceutici: Major Product Offerings
Table 37 CO.DON: Major Product Offerings
Table 38 AnGes: Major Product Offerings
Table 39 GC Pharma: Major Product Offerings
Table 40 JW CreaGene: Major Product Offerings
Table 41 APAC Biotech: Major Product Offerings
Table 42 NIPRO: Major Product Offerings
Table 43 Terumo: Major Product Offerings
Table 44 Orthocell: Major Product Offerings
Table 45 Bluebird bio: Major Product Offerings
Table 46 Global Cell & Gene Therapy Market by Geography 2019?2025 ($ million)
Table 47 Global Cell & Gene Therapy Market by Geography 2019?2025 (%)
Table 48 Global Cell & Gene Therapy Market by Therapy 2019?2025 ($ million)
Table 49 Global Cell & Gene Therapy Market by Therapy 2019?2025 (%)
Table 50 Global Cell & Gene Therapy Market by Applications 2019?2025 ($ million)
Table 51 Global Cell & Gene Therapy Market by Applications 2019?2025 (%)
Table 52 Global Cell & Gene Therapy Market by End-Users 2019?2025 ($ million)
Table 53 Global Cell & Gene Therapy Market by End-Users 2019?2025 (%)
Table 1 Key Caveats
Table 2 Currency Conversion 2013?2019
Table 3 Gene Therapies in Significant Stages of Clinical Pipeline
Table 4 Cell & Gene Therapy Products with Expanding Applications
Table 5 Product Approvals &Launch Details
Table 6 List of Products Received RMAT Designation in 2019
Table 7 List of Products Received PRIME Designation in 2019
Table 8 CAR T-Cell Investigational Products
Table 9 Cost of Kymriah in Different Regions
Table 10 Top Cancer Care Centers Across the Globe
Table 11 Major Cell & Gene Therapy Products Approved Recently in Europe
Table 12 Gilead Sciences: Major Product Offerings
Table 13 Spark Therapeutics: Major Product Offerings
Table 14 Novartis: Major Product Offerings
Table 15 Organogenesis: Major Product Offerings
Table 16 Amgen: Major Product Offerings
Table 17 Osiris Therapeutics: Major Product Offerings
Table 18 Dendreon: Major Product Offerings
Table 19 Vericel: Major Product Offerings
Table 20 Anterogen: Major Product Offerings
Table 21 Tego Sciences: Major Product Offerings
Table 22 JAPAN TISSUE ENGINEERING (J-TEC): Major Product Offerings
Table 23 JCR Pharmaceuticals: Major Product Offerings
Table 24 Medipost: Major Product Offerings
Table 25 MolMed: Major Product Offerings
Table 26 Avita Medical: Major Product Offerings
Table 27 Collplant: Major Product Offerings
Table 28 Biosolution: Major Product Offerings
Table 29 Stempeutics Research: Major Product Offerings
Table 30 Kolon Tissue Gene: Major Product Offerings
Table 31 Orchard Therapeutics: Major Product Offerings
Table 32 Sibiono GeneTech: Major Product Offerings
Table 33 Shanghai Sunway Biotech: Major Product Offerings
Table 34 RMS Regenerative Medical System: Major Product Offerings
Table 35 Takeda Pharmaceutical Company: Major Product Offerings
Table 36 CHIESI Farmaceutici: Major Product Offerings
Table 37 CO.DON: Major Product Offerings
Table 38 AnGes: Major Product Offerings
Table 39 GC Pharma: Major Product Offerings
Table 40 JW CreaGene: Major Product Offerings
Table 41 APAC Biotech: Major Product Offerings
Table 42 NIPRO: Major Product Offerings
Table 43 Terumo: Major Product Offerings
Table 44 Orthocell: Major Product Offerings
Table 45 Bluebird bio: Major Product Offerings
Table 46 Global Cell & Gene Therapy Market by Geography 2019?2025 ($ million)
Table 47 Global Cell & Gene Therapy Market by Geography 2019?2025 (%)
Table 48 Global Cell & Gene Therapy Market by Therapy 2019?2025 ($ million)
Table 49 Global Cell & Gene Therapy Market by Therapy 2019?2025 (%)
Table 50 Global Cell & Gene Therapy Market by Applications 2019?2025 ($ million)
Table 51 Global Cell & Gene Therapy Market by Applications 2019?2025 (%)
Table 52 Global Cell & Gene Therapy Market by End-Users 2019?2025 ($ million)
Table 53 Global Cell & Gene Therapy Market by End-Users 2019?2025 (%)
